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1. Introduction
Despite routine use of ASA before CABG, and lifelong following the revascularization, patients
who undergo CABG remain at high risk of long-term events in any vascular bed (cerebrovas‐
cular, cardiovascular, peripheral). The handicap of management of antiplatelet agents in the
perioperative period of cardiac surgery requires close collaboration between cardiologists,
surgeons and anaesthesiologists. It is necessary to avoid thrombotic complications maintaining
the antiagregation, but balancing bleeding complications. [1]
Combined antiplatelet therapy employing agents from different pharmacological classes is
characterised by good safety and efficacy profiles.
Antiplatelet therapy and antithrombin therapy have been demonstrated to reduce the risk of
cardiac events in patients presenting with acute coronary syndrome, yet all effective therapies
also increase the risk of bleeding. Antiplatelet therapy and antithrombotic therapy have been
demonstrated to favorably modify clinical outcome, and recent trials of revascularization in
ACSs have demonstrated a reduction in the frequency of major cardiac events.[2-14]
Multiple clinical trials showed the favorable benefit/risk ratio of clopidogrel over aspirin
justifying the indication for using clopidogrel in a wide range of at risk patients and in long-
term prevention in various manifestations of atherosclerosis.[2-9]
Antiplatelet and antithrombin therapy can have synergistic actions that reduce the risk of
spontaneous or revascularization, especially percutaneous coronary intervention (PCI)–
related events. On the other hand, all effective antithrombotic agents also increase the risk of
bleeding, especially bleeding that results from vascular access or associated with surgery,
including coronary artery bypass grafting (CABG).
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The Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial
demonstrated that the combination of clopidogrel and aspirin was superior to aspirin alone
for patients hospitalized with non–ST-elevation ACSs.[5] The therapy was in addition to the
current standard of care, including heparin or low-molecular-weight heparin, antianginal
therapy, and revascularization.[5, 6, 15].
Actually the field of the indications of use of the Clopidogrel is being continuously updated.
There are different type of patients who benefit from antiplatelet therapy [16, 17] Moreover
the combination of two antiagregant drugs (mainly ASA and clopidogrel) in high risk patients
is a practice more and more extended [18] and dual antiplatelet therapy is recommended and
has to be maintained at least 12 months after drug eluting stent placement [19].
On the other hand, in patients undergoing coronary artery bypass grafting, immediate
postoperative antiagregant regimens are only regulated for routinely use Aspirin.
Antiplatelet therapy is critical in the management of coronary artery disease. For patients
undergoing coronary artery bypass graft surgery (CABG), controversy remains regarding the
safety of preoperative antiplatelet therapy and the optimal postoperative antiplatelet regimen
to maintain graft patency and reduce ischemic complications.
Despite > 30 years of experience with antiplatelet agents during CABG, questions remain
regarding their perioperative safety and efficacy. The results of continuing randomized
controlled trials should further clarify the role of perioperative aspirin and clopidogrel therapy
and help redefine the modern antiplatelet management of coronary artery bypass patients.
Following surgery, extensive evidence supports the use of aspirin, in doses of 100 - 325 mg
daily, to be administered in 48 h postoperatively and continued indefinitely. Less is known
regarding the use of clopidogrel following CABG, although it is now recommended as
postoperative antiplatelet therapy in patients with recent acute coronary syndromes.[20]
It is very important to identify the optimal timing and dose ofAaspirin following CABG, and
to assess the role of postoperative Clopidogrel therapy.
The recommendations regarding the treatment with Clopidogrel in coronary artery sugery do
not take into consideration the cost-benefit ratio which reflect the usefulness from economic
point of view, probably because of a the complexity of factors of this equation.
2. Objectives
1. To compare the efficacy and safety of Clopidogrel with Aspirin and Aspirin plus Clopi‐
dogrel in patients undergoing surgical coronary revascularisation in the immediate
postoperative period and 1 year after coronary artery bypass grafting depending on the
type of the lesion, on the type of the surgical procedure and on the associated risk factors
for gastrointestinal bleeding.
Artery Bypass292
2. To evaluate the importance and utility of antiplatelet therapy with Clopidogrel early
postoperatively in the intensive care unit (ICU) for the prevention of postoperative
complications
3. To establish the prognostic implications of the type of the perioperative antiagregant
regimen in patients with CABG and to determine which therapy can reduce hospital stay
after cardiac surgery and improve the quality of life of these patients.
4. To determine the indications for using Clopidogrel or Aspirin or Aspirin plus Clopidogrel
in coronary artery surgery depending on the cost-benefit ratio and its economic implica‐
tions.
3. Methods and material
Randomized,, open label three years clinical trial with open study period, carried out on 1200
pts undergoing coronary artery bypass grafing divided in three parallel groups: Group A:
Clopidogrel po 75 mg/day, Group B: Aspirin po 75 mg/day and Group C: Aspirin 75mg plus
Clopidogrel 75mg once daily.
The main phases of the study protocol were: (Figure 1)
• Enrollment phase – there were enrolled one thousand and two hundred patients undergoing
CABG, in the immediate postoperative period
• Active treatment phase – after randomisation all patients received antiagregant therapy:
◦ Group A with Aspirin 75 mg daily
◦ Goup B with Clopidogrel 75 mg daily
◦ Group C with combination of Aspirin 75 mg with Clopidogrel 75 mg.
The treatment began the second day postoperatively and lasted no less than 1 year postoper‐
atively.
• follow –up phase – all patients were evaluated clinically and paraclinically daily for the first
ten days and at one, three, six months and one year postoperatively. Patients were followed
for a minimum of 1 to a maximum of 3 years, regardless of discontinuation of the study
drug. Follow-up assessments took place at 1, 3, 6, and 12 months for all patients and at 1, 2
and 3 years for patients randomized early in the study.
4. Eligibility criteria
The study included all patients undergoing coronary artery bypass grafting, who underwent
surgery in an Emergency Institute for Cardiovascular Diseases between January 1st 2008 and
May 1st 2011 who did not have the non – eligibility criterias.
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Patients were over the age of 21, and able to provide informed consent and agreed to comply
with all protocol-specified procedures.
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Clopidogrel 75mg 
po every 24 h 
Control days 1-10, 15 
months 1, 3, 6 and 1 
year after CABG 
Aspirin 75 mg po every 
24 h 
1 day after 
CABG 
Randomization 
Group A 
Enrollment phase 
Active treatment 
(min 1 year) Follow up 
Group B 
Control days 1-10, 15, 
months 1,3,6 and 1 year 
after CABG 
Group C Aspirin75mg+Clopidogre
l 75mg po every 24 h 
Control days 1-10, 15, 
months 1, 3, 6 and 1 
year after CABG 
Figure 1. Treatment protocol phases
5. Non-eligibility criteria
Patients were excluded from enrolment in the study if any of the following criteria were met:
• Active internal bleeding or risk of hemorrhagic diathesis
• Q-wave myocardial infarction within 24 hours prior to randomization
• Cardiogenic shock.
• Serum Creatinine ≥ 3.0 mg/dl
• severe hepatic failure with ALT or AST > 3x ULN
• Previous use of a GPIIb/IIIa antagonist within 7 days
• Need for long-term anticoagulant or NSAID use
• Failed PCI within 2 weeks prior to randomization
• Active participation in another clinical trial
• Failure to comply with the hospital protocol
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6. Study drop out criteria
The  occurrence  of  adverse  events  (skin  reactions,  gastrointestinal  symptoms,  active  in‐
ternal  bleeding)
Failure to comply with the hospital protocol/ absence to follow-up
The protocol was approved by the institute management, and every patient signed the
informed consent form.
The essential inclusion criteria (gender,mean age, comorbidities, number of grafts per patient,
the type of the grafts (arterial or venous) and the mean left ventricular ejection fraction, left
ventricular diastolic performance and left atrial dimensions (diameters and area), the duration
of treatment and assessment criteria were similar in the three treatment groups (p<0.0001). All
patients received standard therapy including beta blockers, IEC, statins throughout the study
period. The patients with exclusive arterial revascularisation also received calcium channel
blockers agents but their number was similar in the three groups of study.
Clinical and laboratory parameters were initially assessed, at baseline and at each visit until
the end of the study period.
The clinical measurements included: NYHA class for heart failure, presence of angina pectoris,
ventricular rhytm, patient compliance and quality of life.
Laboratory parameters included: the usual blood tests (platelet count, hemoglobin, hematocrit,
aminotransferases, LDH, biochemistry cholesterol and tryglycerides levels), electrocardio‐
gram(with the evaluation of rhythm, frequence and ST-T elevation), 24 hours ECG Holter
monitoring for silent ischemia, stress efort test at 1,3,6 months and 1 year postoperatively and
when angina occurred (Bruce or Bruce modified protocol), echocardiography (with assessment
of the LV dimensions, ventricular sistolic and diastolic performance, ventricular walls
contractility - segmental kinetics, mitral regurgitation degree) and coronarography at 1 year
when the other tests where positive for ischemia. Also, at each visit were recorded the
occurrence of major and minor bleeding episodes, gastrointestinal symptoms, skin reactions,
thrombocytopenia and lab tests abnormalities.
24 hours ECG Holter used a 12 channels monitoring with the evaluation of conduction or
rhythm disturbances or occurrence of silent ischemia.
Treadmill stress test was done at 1, 3, 6 months and at 1 year postoperatively and used Bruce
or Bruce modified protocol. If the stress test or Holter monitoring diagnosed ischemia at one
follow up visit, this was the indication for performing coronarography.
Early development of graft occlusion was diagnosed based on clinical criteria and through
electrocardiogram, Holter monitoring, thoracic and transesophageal echocardiography. The
appearance of gastrointestinal bleeding was diagnosed using clinical evaluation, endoscopy
and colonoscopy.
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6.1. Primary and secondary endpoints
The looked at all-cause mortality and major cardiac events, namely cardiac mortality, myo‐
cardial infarction or need for target lesion revascularization. The most important endpoints
used for the estimation of the medium term prognosis were:
The primary endpoint (efficacy endpoint) was a composite outcome cluster of 30-day mortal‐
ity, myocardial infarction, in-hospital and at 1 year occurrence of graft occlusion (efficacy
endpoints), total hospital stay and immobilization (measured in days), Intensive Care Unit
length of stay and cost, quality of life. Quality of life was appreciated using a scale from one
to ten calculated on the base of a questionnaire filled by the patients at each visit
The secondary endpoints at 30 days looked at in-hospital major peripheral or bleeding
complications (including surgical bleeding complications, transfusion of at least two units of
blood, intracranial bleeding, retroperitoneal bleeding, overt hemorrhage), neutropenia (<1.5 x
109 per litre), thrombocytopenia (<100 x 109 per litre), early discontinuation of the study drug
due to a non-cardiac adverse event (including death of non-cardiac origin) (safety endpoint).
The data collected represented the fields of a database in the Visual Fox Pro computer program.
Data were processed by means of computers, using the Excel, EpiInfo, Systat and SPSS
programs for multivariate regression analysis and relative risk and correlation coefficient
calculation
No confirmatory statistical hypothesis was pre-specified, but a detailed analysis plan was
defined before the database was locked. This analysis plan was based on generating risk ratios
and CIs (CI=confidence index) for the pairwise comparisons of primary interest. These
comparisons were presented with the two - sided 95% CI of the relative risk and with normal
p values. For the primary endpoints Kaplan-Meier curves were constructed and log-rank tests
were done. For each endpoint, a two-sided 95% CI was also calculated and an overall Chi
square test, comparing the three treatment groups was done [19, 21, 25].
The frequency of the primary efficacy plus safety endpoint for the Aspirin group as a reference
group was 17,7%. On the basis of phase-II studies we assumed that the experimental groups
with Clopidogrel and Aspirin plus Clopidogrel would result in better, or at least similar
outcomes when compared with standard treatment. The sample size and power calculations
were therefore based on non-inferiority of the experimental group versus the reference group.
The study has 80% power to exclude, with 95% confidence (one-sided), a 1% higher rate of the
primary endpoints compared with the reference group, provided the point estimate in the
experimental treatment group was 1,7% lower for the efficacy endpoint and 2% lower for the
efficacy and safety endpoint. [2-11, 13-18, 22]
7. Patients
The study included 1200 patients undergoing coronary artery bypass grafing with arteries
(internal mammar, radial, gastroepiploic) or inverted saphenal veins. The patients were
Artery Bypass296
randomised to receive Clopidogrel 75 mg daily or Aspirin 75 mg daily or Aspirin plus
Clopidogrel 75mg daily one day after surgery and in the postoperative period for no less than
1 year.. The patients undergoing also venticular remodelling for aneurysms were not taken in
our study.
The baseline characteristics were similar in the three arms of the study (Table 1). Overall, the
study populations were similar to those of previous trials on antiagregants.
Group A –
397 pts
Group B- 401
pts
Group C-
402 pts
Mean (SD) age (years) 62,3 (12) 62,5 (13) 62,4(12)
Age"/>70 years 13,85% 14,21% 14,43%
Women 25,94% 26,18% 26,62%
Family history of heart disease (%) 49,62% 50,12% 49,75%
Dislipidemia (%) 75,06% 75,81% 76,37%
Prior myocardial infarction (%) 33,50% 33,91% 34,58%
NYHA class "/>II 20,15% 20,70% 20,89%
Prior stroke (%) 6,29% 6,73% 6,96%
Peripheral arterial disease 9,82% 9,72% 10,45%
Atrial fibrillation 6,04% 6,48% 6,47%
Hypertension 65,49% 66,58% 64,92%
Diabetes mellitus 25,19% 25,43% 25,12%
Current smoker 26,45% 26,43% 25,87%
Re-intervention (previous coronary artery surgery) 8,82% 8,98% 8,95%
Table 1. Baseline characteristics
The medications used chronically by the patients at the time of randomization were similar in
the Aspirin, Clopidogrel and Aspirin plus Clopidogrel treatment arms and are are listed in
Table 2
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Group A –
397 pts Group B- 401 pts
Group C-
402 pts
Digoxin 23,68% 23,94% 24,13%
ACE inhibitors 67,25% 68,58% 63,68%
Angiotensin II inhibitors 24,43% 23,69% 25,12%
Beta blockers 89,92% 89,28% 90,29%
Aspirin before surgery 61,46% 63,84% 65,17%
Calcium channel blockers 25,44% 25,93% 26,37%
Diuretics 19,90% 20,70% 20,39%
Aldactone 21,91% 21,94% 20,89%
Lipid lowering agents 89,92% 93,76% 94,28%
Table 2. Number of patients who received concomitant medications during stay in hospital
61,46% of patients received Aspirin before surgery in group A, respectively 63,84% in group
B and 65,17% in group C.
The primary efficacy and efficacy plus safety endpoints and their individual components in
the treatment groups are shown in Table 3.
The clinical diagnosis at the time of randomization was similar in the three treated arms of the
study:
• Over half of the patients presented with unstable angina (49,62% in group A, 51,63% in
group B and 53.48% respectively in group C).
• Approximately one in five-six patients had experienced a recent myocardial infarction
(16.37% in group A, 21,94% in group B and 22.39% respectively in group C).
• About a third presented with stable angina or another diagnosis requiring antiagregant
regimen (aproximatively 33,6% in each treatment arm - 33.75% in group A, 33,66% in group
B, 33,58% in group C).
8. Statistics (Figure 2, 3)
The data base was done using Visual Fox Pro programme. The main variables used were:
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• Prediction variables :
◦ patient ID Data
◦ preoperative diagnosis
◦ surgical risk (calculated using a scale from 1 to 10 taking into account different preoper‐
ative parameters: age, co-morbidities, severity of cardiac lesions (NYHA class), type and
duration of surgical intervention, associated risk factors)
◦ type of surgical intervention
◦ specific variables related to the surgical performance: duration of surgical intervention,
intraoperative complications
◦ ICU duration and complications occured
• • Outcomes variables:
◦ presence and type of postoperative complications
◦ death and its causes.
The statistical analysis was performed using the SYSTAT and SPSS programmes for:
• Measurement of the power of association between the prediction variables and outcomes
using different tests depending on the type of variables:
◦ for qualitative variables: CHI square test or Fischer exact test
◦ for quantitative variables: T test (Student test), ANOVA test or U test depending on
samples volumes and Kruskal Wallis nonparametric tests or other methods of statistical
correlation as analysis of simple linear and multivariate regression
• Relative Risk calculation and the 95% confidence limits for treatment groups
• Cost-benefit ratio calculation for using different antiplatelets agents after coronary artery
bypass grafting. It was determined using a special programme, which used the data from
the database and different economic data from specialized departments from our Institute,
in order to perform the assessment of the efficiency of different antiplatelet therapies
following coronary artery surgery.
The calculation of the cost-benefit ratio for each type of treatment and for routinely use
clopidogrel in CABG was done taking into account the following parameters:
• parameters related to the type of the treatment
◦ cost of the treatment for each patient
◦ number of supplementary echographic and endoscopic examinations per patient
◦ number of bleeding episodes and cost per patient
◦ global cost/ patient
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• parameters related to surgical intervention
◦ early postoperative mortality rates for surgical intervention (global and specific depend‐
ing on individual risk and type of the antiagregant regimen)
◦ in hospital and at 1 year graft occlusion/myocardial infarction/severe bleeding on
subgroups of patients taking into account the individual risk
◦ immediate and long term postoperative complications rates depending on the type of the
antiagregant regimen
◦ ICU length of stay and cost
◦ quality of life at 1 month and 1 year postoperatively on risk subgroups and on type of
surgical interventions depending on the type of the antiagregant regimen
• Parameters related to the patient
◦ age
◦ gender
◦ co-morbidities
◦ associated risk factors.
Using the above mentioned parameters, the special programme calculated a risk score per
patient on types of treatment and the cost of routinely use clopidogrel in cabg patients, which
was used then for estimation of the cost-benefit ratio associated with the type of the antiagre‐
gant regimen
Data were grouped on types of surgical interventions according to the exposure level to the
risk factors. For each exposure level there were introduced the number of patients taking
Clopidogrel (cases) and the number of patients who have not taken Clopidogrel (controls).
The confounders were controlled by stratification.
Data interpretation was performed taking into account the following hypothesis:
• a cost-benefit report >1 was considered unfavourable from economic point of view; for these
patients the routine use of Clopidogrel as antiplatelet therapy after coronary artery bypass
surgery was considered as having uncertain indication;
• a cost-benefit report =1 was considered neutral and included the patients subgroups
classified as relative indication for the routine use of clopidogrel as antiplatelet therapy after
coronary artery bypass surgery, risks and benefits of using that therapy it being appreciated
on case to case basis, depending on the risk and benefit for each patient;
• a cost-benefit report <1 was considered favourable from economic point of view; for these
patients the routine use of Clopidogrel as antiplatelet therapy after coronary artery bypass
surgery was considered as having a standard indication, being recommended in each case.
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Figure 2. Statistic methodology
Cost-benefit ratio calculation for  routinely use Clopidogrel postCABG
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Figure 3. Statistical analysis and cost-benefit report calculation
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9. Results
The  main  conclusion  of  our  study  was  that  using  Clopidogrel  single  or  associated
with  Aspirin  for  antiplatelet  treatment  in  the  immediate  postoperative  period in  CABG
patients  is  more effective  than Aspirin  alone,  with a  better  cost-benefit  report.  The cost
benefit  report  associated  with  using  Aspirin  plus  Clopidogrel  was  almost  two  times
higher than with Aspirin alone (Figure 4)
The  incidence  of  myocardial  infarction  and  death  following  graft  thrombosis  was  21%
in  Aspirin  group,12%  in  Clopidogrel  group  and  respectively  7%  in  aspirin  plus  Clopi‐
dogel  group.
Figure 4. Cost-benefit report depending on the type of antiplatelet treatment in CABG patients
Relative risks and 95% confidence indexes for primary efficacy composite endpoints (30 days
mortality, myocardial infarction, inhospital graft oclusion, hospital stay and immobilization
(days), Intensive Care Unit length of stay and cost, quality of life) were different depending
on the patients age, NYHA class, LVEF, the severity of associated MR, but, in all cases were
lower among patients treated with Clopidogrel associated with Aspirin than among those
treated with Aspirin alone
Also, there were different depending on the patients age, NYHA class, LVEF and associated
severe mitral regurgitation.
Conventional statistical testing for Clopidogrel plus Aspirin versus Clopidogrel alone versus
Aspirin alone resulted in p values of 0,0002 and 0,0003 respectively for the primary efficacy
plus safety composite endpoints.
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 Figure 5. Relative risks and 95% Confidence Indexes for primary efficacy composite endpoints in the study groups
At hospital discharge and at 30 days, the combined efficacy and safety outcome endpoints
were smaller in Clopidogrel plus Aspirin group.
For the primary efficacy plus safety endpoint (30 day mortality, inhospital graft oclusion or
inhospital major bleeding), the rates were smaller for Clopidogrel plus Aspirin group, as the
rates of in-hospital death
In-hospital graft oclusion and myocardial infarction occurred rarely in patients treated with
Clopidogrel plus Aspirin compared with the patients treated with Aspirin alone. Major hemor‐
rhagic events were similar in the study groups. Concerning the duration of the hospitalisation
and imobilisation, there were a little bit smaller in Clopidogrel plus Aspirin group. (Figure 6)
Figure 6. Frequency of composite and single endpoints at hospital discharge and at 30 days
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On long term, the incidence of death, myocardial infarction, and revascularization occurring
at one year following CABG was greater in Aspirin group compared with Clopidogrel and
Clopidogrel plus Aspirin groups (15% versus 12% versus 10%)
The Kaplan Meier curves for primary efficacy and safety endpoints showed a smaller proba‐
bility for death, myocardial infarction or graft oclusion in Clopidogrel plus Aspirin group
(Figure 7).
Early after treatment, the curves for Clopidogel associated or not with Aspirin started to
separate from the one of Aspirin alone. At 30 days, differences in the primary endpoints
between the three groups were already present.
Until the end of the follow up, for the primary efficacy endpoint and for the primary efficacy
plus safety endpoint, event rates were abut two times higher for Aspirin group compared with
Clopidogrel plus Aspirin group with log rank tests highly significant and significant p values
(p<0,0001).
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) 
Days to death or revascularisation 
Clopidogrel plus Aspirin versus Clopidogrel versus Aspirin - Kaplan-
Meier curves for primary efficacy plus safety endpoint 
Clopidogrel plus Aspirin Clopidogrel Aspirin
Figure 7. The Kaplan Meier curves for primary efficacy and safety endpoints
Concerning antiagregany therapy complications, the dates on in-hospital strokes are sum‐
marized in Figure 8.
There were no significant differences between the three groups regarding major hemorrhage
and thrombocytopenia. Minor hemorrhage occurs more frequently in patients taking Aspirin.
Total stroke and ischemic stroke rates were similar in the three groups. A few hemorrhagic
conversions were seen in each of the tthree treatment groups. More minor or major bleeding
complications and blood transfusions were also seen in the aspirin alone or associated with
clopidogrel groups compared with clopidogrel alone group, although these differences were
not significant.
Significantly more major bleeding complications (p=0,0001), more transfusions (p=0,002) and
a higher rate of thrombocytopenia (p=0,001) were seen in patients with associated treatment
with anticoagulants, in patients older than 75 years and in diabetics, the rate of major bleeding
complications was three times higher in those with associated anticoagulant therapy (4%ver‐
sus 14% and 2% versus 7% respectively
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Figure 8. Hemorhagic and ischemic postoperative complications in the study groups.
The probability of early graft oclusion and perioperative myocardial infarction was smaller
with Clopidogrel alone or associated with Aspirin versus Aspirin alone, the associated relative
risks being negative because the studied drugs worked as protection factors for these perio‐
perative complications. (Figure 9)
As we seen before, the relative risks for the most severe antiagregant therapy complications,
hemoragic stroke were similar in the three study groups
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or hemorrhagic stroke 
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Figure 9. Relative risk for early graft thrombosis, acute myocardial infarction or hemorrhagic stroke
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10. Discussions
Multiple clinical trials showed the favorable effects of Clopidogrel alone or combined with
Aspirin extending the indication for using Clopidogrel in a wide range of at risk patients and
in long-term prevention in various manifestations of atherosclerosis.
In recent years, enormous growth in the use of coronary stenting procedures has resulted in a
significant decrease in restenosis rates, while acute and sub-acute stent thrombosis remain a
significant potential complication. It has been shown, however, that the risk of acute and sub-
acute stent thrombosis is greatly reduced by the administration of antiplatelet therapies
following stenting. Much clinical experience with combination of aspirin and ticlopidine has
been gained, however ticlopidine has been shown to be associated with rare risk of haemato‐
logical adverse events.
The CLASSICS study demonstrated the safety and efficacy of clopidogrel (with or without
loading dose) in combination with aspirin for use following coronary stenting.
A large randomized trial has demonstrated that the acute administration of clopidogrel—a
long-acting antiplatelet therapy—to patients with non–ST-segment elevation acute coronary
syndromes (NSTE ACS) can reduce subsequent risk for death, myocardial infarction, or stroke
by 20% when continued for a mean duration of nine months [21]. However, single-center case
series have demonstrated that, in patients requiring coronary artery bypass graft surgery, the
use of Clopidogrel is associated with increased risk of perioperative bleeding and a need for
transfusion [22- 26].
This risk appears to be time dependent. For example, post-hoc data analysis from the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent Events) trial revealed that bleeding risks
were increased when patients had CABG surgery within 5 days of clopidogrel treatment but
not when surgery was delayed for >5 days after treatment with clopidogrel [21]
These findings are reflected in the American College of Cardiology/American Heart Associa‐
tion (ACC/AHA) guidelines for the acute management of patients with NSTE ACS, which
endorse the acute use of clopidogrel but also recommend withholding clopidogrel for at least
5 days before CABG surgery (27).
Adherence  in  community  practice  to  this  guidelines  recommendation  is  very  unclear.
has  not  been  characterized previously.  There  are  studies  trying  to  characterize  patterns
of  Clopidogrel  use  before  CABG  and  to  examine  the  time-dependent  risks  for  postop‐
erative  transfusion  among  NSTE  ACS  patients  treated  at  264  hospitals  participating  in
the  CRUSADE  (Can  Rapid  Risk  Stratification  of  Unstable  Angina  Patients  Suppress
Adverse  Outcomes  With  Early  Implementation  of  the  ACC/AHA  Guidelines)  National
Quality  Improvement Initiative [15,  28-  29].
Combined antiplatelet therapy was also studied in a lot of trials and most of them showed
good safety and efficacy profiles. Antiplatelet therapy and antithrombin therapy have been
demonstrated to reduce the risk of cardiac events in patients presenting with acute coronary
syndrome, yet all effective therapies also increase the risk of bleeding. Antiplatelet therapy
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and antithrombotic therapy have been demonstrated to favorably modify clinical outcome,
and recent trials of revascularization in ACSs have demonstrated a reduction in the frequency
of major cardiac events[2-14].
The benefits versus risks of early and long-term clopidogrel therapy (freedom from CV death,
MI, stroke, or life-threatening bleeding) are similar in those undergoing revascularization
(CABG or PCI) and in the study population as a whole. Overall, the benefits of starting
clopidogrel on admission appear to outweigh the risks, even among those who proceed to
CABG during the initial hospitalization.
Actually the field of the indications of use of the antiagregant therapy is being continuously
updated.The role of the aspirin in the primary prevention has extended its prescription based
on related factors of cardiovascular and/or neurological risk. Moreover the combination of two
antiagregant drugs (mainly Aspirin and clopidogrel) in high risk patients is a practice more
and more extended [18]. Dual antiplatelet therapy has to be maintained at least 12 months after
drug eluting stent placement and, in this patient a specific protocol of antiaggregation in type,
combination and duration need to be applied [30, 31].
For patients undergoing coronary artery bypass graft surgery, controversy remains regarding
the safety of preoperative antiplatelet therapy and the optimal postoperative antiplatelet
regimen to maintain graft patency and reduce ischemic complications. There are also of this
systematic reviews trying to evaluate the risks and benefits of preoperative aspirin and
clopidogrel therapy, to identify the optimal timing and dose of aspirin following CABG, and
to assess the role of postoperative clopidogrel therapy.[20]Following surgery, extensive
evidence supports the use of aspirin, in doses of 100 - 325 mg daily, to be administered in 48
h postoperatively and continued indefinitely. Less is known regarding the use of clopidogrel
following CABG, although it is now recommended as postoperative antiplatelet therapy in
patients with recent acute coronary syndromes.Despite > 30 years of experience with antipla‐
telet agents during CABG, questions remain regarding their perioperative safety and efficacy.
The results of continuing randomized controlled trials should further clarify the role of
perioperative aspirin and clopidogrel therapy and help redefine the modern antiplatelet
management of coronary artery bypass patients.
Also, the optimal aspirin dose for the prevention of cardiovascular events remains controver‐
sial.[32]: Daily aspirin doses of 100 mg or greater were associated with no clear benefit in
patients taking aspirin only and possibly with harm in patients taking clopidogrel. Daily doses
of 75 to 81 mg may optimize efficacy and safety for patients requiring aspirin for long-term
prevention, especially for those receiving dual antiplatelet therapy.
The response to aspirin and/or clopidogrel and its impact on graft patency after off-pump
coronary artery bypass grafting is characterised by individual variability, but, overall com‐
bined clopidogrel and aspirin overcome single drug resistances, were are safe for bleeding and
improve venous graft patency. [33]
At first sight, clopidogrel appears to be undesirable for cardiac surgeons: antiplatelet therapy
can increase the risk of bleeding during coronary artery bypass graft surgery (CABG).1
Traditionally, many surgeons have felt that, with impeccable technique, their personally
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constructed grafts would be nearly ‘immune’ to thrombosis, even without antiplatelet therapy.
However, it could theoretically reduce the risk for early vein graft failure, which is predomi‐
nantly thrombosis related.
There are three different principal mechanisms that play a role in vein graft failure during
postoperative periods: early (<1 month): thrombosis; related to technical factors, Intermediate
(1 to 12 months): intimal hyperplasia and Later postoperative (>12 months): accelerated
atherosclerosis [34]
Concern about possible hemorrhagic complications arising from use of oral antiplatelet agents
in immediate proximity to coronary artery bypass graft (CABG) surgery leads many clinicians
to avoid or discontinue these agents preoperatively. Recent evidence suggests that.the modest
hemorrhagic risk may be acceptable, given the clinical benefits of sustained antiplatelet
therapy in preventing graft occlusion and ischemic complications pre- and post-CABG. [35]
Also, other analysis provide insight into patterns of clopidogrel use and outcomes in the setting
of CABG performed on patients with NSTE ACS [36] and found that as many as 30% of patients
currently receive clopidogrel before CABG surgery, and, of these, nearly 90% have surgery
within 5 days of treatment, contrary to the ACC/AHA guidelines recommendations. These
data demonstrating a modest increase in transfusion risk in part reflect a more stable estimate
of risks based on a much larger case sample in the CRUSADE Initiative.
The benefits versus risks of early and long-term clopidogrel therapy (freedom from CV death,
MI, stroke, or life-threatening bleeding) were similar in those undergoing revascularization
(CABG or PCI) and in the study population as a whole. Overall, the benefits of starting
clopidogrel on admission appear to outweigh the risks, even among those who proceed to
CABG during the initial hospitalization.[26]
Data from the Antiplatelet Trialists’ Collaboration support the use of antiplatelet therapy
(mostly data for aspirin) after CABG and further data support the initiation of aspirin within
48 hours of CABG. The CURE trial provides the opportunity to explore the combined use of
aspirin and clopidogrel for those undergoing CABG.[26]
Clopidogrel offers multiple advantages in acute and chronic use in coronary intervention. The
favorable benefit/risk ratio of clopidogrel over aspirin established by CAPRIE, combined with
its characteristics related to rapid onset of action, loading dose, pre-treatment efficacy and ease
of use, justify the consideration of using clopidogrel in a wide range of at risk patients and in
long-term prevention in various manifestations of atherosclerosis / atherothrombosis.
Combined antiplatelet therapy employing agents from different pharmacological classes after
CABG was characterised by good safety and efficacy profiles. The absence of interaction, and
the potential synergistic effect when used with other antithrombotic agents, will allow
clinicians to optimise treatment in acute situations. Combination therapy, using clopidogrel
and other drugs commonly administered for a range of cardiovascular and other disorders,
appears safe after CABG.
Despite  routine  use  of  ASA before  CABG,  and lifelong  following  the  revascularization,
patients  who  undergo  CABG  remain  at  high  risk  of  long-term  events  in  any  vascular
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bed  (cerebrovascular,  cardiovascular,  peripheral).  The  incidence  of  death,  MI,  and  re‐
vascularization occurring at  one  and three-year  following a  CABG is  greater  than 15%.
3.  Therefore,  patients  who  undergo  CABG  could  benefit  from  long-term  therapy  that
provides  improved protection  against  all  types  of  atherothrombotic  events  such as  my‐
ocardial  infarction,  ischemic strokes,  and vascular  death.
11. Study limitations
First, our comparisons of clinical outcomes by treatment strategy were observational. Al‐
though we adjusted all comparisons for baseline clinical factors, we cannot exclude any
persistent unmeasured confounding. Nonetheless, because a randomized clinical trial
evaluating the benefits and risks of different antiagregant regimen of patients undergoing
CABG is unlikely to be undertaken, this study is the first to provide insight into the scope of
this issue at a national level.we considered the diagnostic of ischemia using stress test, Holter
monitoring and, in case of a positive result, invasive coronarography as sufficient. Second, we
did not collect data on the incidence of re-exploration at 2 or three years after CABG, although
we had some information about that and we did nor perform routinely coronarography at 1
year postoperatively to all patients.
12. Conclusions
1. Antiplatelet therapy with Clopidogrel plus Aspirin in the immediate postoperative period
in patients with CABG was associated with an better cost-benefit report, proving to be
more effective than Aspirin alone.
Taking into account both efficacy and safety, the combined antiplatelet therapy with
Clopidogrel and Aspirin emerged as the best treatment in this trial.
2. The favourable cost/benefit ratio of Clopidogrel over Aspirin established by this study,
combined with its characteristics related to rapid onset of action, loading dose, pre-
treatment efficacy and ease of use, justify the consideration of routinely using Clopidogrel
in CABg patients and in long-term prevention in various manifestations of atherosclerosis
3. Taking into account cost-benefit report when comparing antiplatelet strategies after
CABG,treatment with Aspirin alone was associated with an cost benefit report almost 1
in terms of reducing mortality and graft oclusion, Clopidogrel alone with a little bit more
than one and the asociated therapy had an cost benefit ratio about 3, emerged as the best
treatment inthis trial. It should be regarded as an attractive alternative pharmacological
antiplatelet strategy in the immediate postoperative period in CABG patients,deserving
further studies
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